LivaNova (LIVN) return on equity (ROE)

Return on equity · fiscal 2025
-20.2%

LivaNova (LIVN) earned a return on equity of -20.2% in fiscal 2025 (the year ended December 31, 2025). That is 25.0 percentage points lower than the 4.8% of fiscal 2024. Figures as of 18 Nov 2026, 00:16 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-20.2%
Change on fiscal 2024
−25.0 pts
Highest on record
21.2%fiscal 2014
Lowest on record
-31.4%fiscal 2020
Fiscal years on record
132013–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

LivaNova return on equity (ROE), in more detail

Across the 13 fiscal years on record (2013–2025), the highest was 21.2% in fiscal 2014 and the lowest -31.4% in fiscal 2020. The fiscal 2025 figure is higher than in 8% of the 12 earlier fiscal years on record, whose median is -2.5%.

History · 13 fiscal years

Return on equity by fiscal year

LivaNova return on equity (ROE), year by year

LivaNova (LIVN) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-20.2% 25.0 pts down
20244.8% 3.4 pts up
20231.4% 8.5 pts up
2022-7.1% 3.3 pts up
2021-10.5% 21.0 pts up
2020-31.4% 20.0 pts down
2019-11.4% 1.2 pts up
2018-12.6% 11.2 pts down
2017-1.4% 2.3 pts up
2016-3.7% 24.6 pts down
201520.9% 0.3 pts down
201421.2% 1.0 pts up
201320.2%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of LivaNova and comparable companies
CompanyReturn on equityFiscal year
Edgewise Therapeutics EWTX-32.1%2025
LivaNova LIVN-20.2%2025
Dianthus Therapeutics DNTH-32.9%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on LIVN

LivaNova, figure by figure

LivaNova (LIVN) overview: price, valuation and scorecardAll health care companies by market value

LivaNova return on equity (ROE): questions and answers

What is LivaNova's return on equity?

LivaNova (LIVN) earned a return on equity of -20.2% in fiscal 2025 (the year ended December 31, 2025). That is 25.0 percentage points lower than the 4.8% of fiscal 2024.

Is LivaNova's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 8% of the 12 earlier fiscal years on record, whose median is -2.5%.

What are the highest and lowest return on equity figures on record for LivaNova?

Across the 13 fiscal years on record (2013–2025), the highest was 21.2% in fiscal 2014 and the lowest -31.4% in fiscal 2020.

How is LivaNova's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “LivaNova (LIVN) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/LIVN/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.